The development study of the new gene therapy that assumed telomerase activity for urinary cancers.

• Project/Area Number: 18591754
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Single-year Grants
• Section: 一般
• Research Field: Urology
• Research Institution: Okayama University
• Principal Investigator: KAKU Haruki Okayama University, 医学部・歯学部附属病院, 講師 (60346426)
• Co-Investigator(Kenkyū-buntansha): NASU Yasutomo 岡山大学, 大学院・医歯薬学総合研究科, 准教授 (20237572) ; FUJIWARA Toshiyoshi 岡山大学, 医学部・歯学部附属病院, 准教授 (00304303) ; KAGAWA Syunsuke 岡山大学, 医学部・歯学部附属病院, 助教 (00362971)
• Research Collaborator: HUANG Peng 岡山大学, 大学院・医歯薬学総合研究科, 大学院生
• Project Period (FY): 2006 – 2008
• Project Status: Completed (Fiscal Year 2008)
• Budget Amount: ¥3,970,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥570,000); Fiscal Year 2008: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000); Fiscal Year 2007: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000); Fiscal Year 2006: ¥1,500,000 (Direct Cost: ¥1,500,000)
• Keywords: 腫瘍学 / 尿路性器癌 / 遺伝子治療 / テロメラーゼ・プロモーター / 制限増殖型アデノウイルス

Research Abstract

本研究は尿路性器癌に対するテロメラーゼ活性を標的とした新規ウイルス療法の開発研究を目的とした。研究期間内に転移癌を含む前立腺癌、腎癌に対する有効性、他の療法との併用効果の増強が確認された。一方、Telomelysinと新規癌抑制遺伝子REICとの併用効果は癌種によって効果は一定ではなく、新規ウイルスArmed-Telomelysin(Telomelysin-REIC)の作製に至らなかった。

Research Products

• [Journal Article] Direct and distant antitumor effects of a telomerase-selective oncolytic adenoviral agent, OBP-301, in a mouse prostate cancer model (2008)
  • Author(s): Huang P., Watanabe M., Kaku H., Kashiwakura Y., Chen J., Saika T., Nasu Y., Fujiwara T., Urata Y., Kumon H
  • Journal Title: Cancer Gene Therapy 15 Pages: 315-22
  • Peer Reviewed
• [Journal Article] Direct and distant antitumor effects of a telomerase-select ive oncolytic adenoviral agent, OBP-301, in a mouse prostate cancer model. (2008)
  • Author(s): Peng Huang
  • Journal Title: Cancer Gene Therapy 15 Pages: 315-322
  • Peer Reviewed
• [Journal Article] Heat shock proteins play a crucial role in tumor-specific apoptosis by REIC/Dkk-3 (2007)
  • Author(s): Abarzua F., Sakaguchi M., TaniSonegawa H., Li D.W., Edamura K., Kobayashi T., Watanabe M., Kashiwakura Y., Kaku H., Saika T., Nakamura K., Nasu Y., Kumon H., Huh NH
  • Journal Title: Int J Mol Med. 20 Pages: 37-43
  • Peer Reviewed
• [Journal Article] Suicide gene therapy with adenoviral delivery of HSV-tK gene for patients withlocal recurrence of prostate cancer after hormonal therapy (2007)
  • Author(s): Nasu Y., Saika T., Ebara S., Kusaka N., Kaku H., Abarzua F., Manabe D., Thompson T.C.,Kumon H
  • Journal Title: Mol Ther. 15 Pages: 834-840
  • Peer Reviewed
• [Journal Article] Routine transurethral biopsy of the bladder is not necessary to evaluate the response to bacilluscalmette-guerin therapy (2007)
  • Author(s): Murakami T., Ebara S., Saika T., Irie S., Takeda K., Maki Y., Miyaji S., Manabe D., Kaku H., Nasu Y., Tsushima T., Kumon H
  • Journal Title: Acta Med Okayama 61 Pages: 341-344
  • Peer Reviewed
• [Journal Article] 前立腺癌-基礎・臨床研究のアップデート-II.臨床研究 治療 遺伝子治療 (2007)
  • Author(s): 賀来春紀, 那須保友, 雑賀隆史, 公文裕巳
  • Journal Title: 自殺遺伝子・サイトカイン遺伝子を用いた遺伝子治療 65 Pages: 522-527
• [Journal Article] Combination chemotherapy with estramustine phosphate, ifosand cisplatin for hormone-refractory prostate cancer (2006)
  • Author(s): Kaku H., Saika T., Tsushima T., Nagai A., Yokoyama T., Abarzua F., Ebara S., Manabe D., Nasu Y., Kumon H
  • Journal Title: Acta Med Okayama 60 Pages: 43-49
  • Peer Reviewed
• [Journal Article] 岡山大学における前立腺癌遺伝子治療研究の現況と展望-ベーシックリサーチからトランスレーショナルリサーチヘー (2006)
  • Author(s): 賀来春紀, 藤原俊義, 公文裕巳, 渡部昌実, 黄鵬, 陳 潔, 谷本竜太, フェルナンド アバルスア, 枝村康平, 真鍋大輔, 江原 伸, 雑賀隆史, 那須保友, 公文裕巳
  • Journal Title: 西日本泌尿器科 69 Pages: 221-229
  • Peer Reviewed
• [Journal Article] Direct and distant antitumor effects of a telomerase-selective oncolytic adenoviral agent, OBP-301, in a mouse prostate cancer model.
  • Author(s): Peng Huang
  • Journal Title: Cancer Gene Therapy (in press)
  • Peer Reviewed
• [Presentation] In vitro and In vivo Molecular Evidence for better Therapeutic Efficacy of telomerase-selective oncolytic adenovirus (OBP-301) and Interleukin-2 in renal cell carcinoma (2008)
  • Author(s): Huang P
  • Organizer: The World 5^<th> Gene Therapy Congress
  • Place of Presentation: Shijiazhuang , China
  • Year and Date: 2008-09-21
• [Presentation] In vitro and In vivo Molecular Evidence tor better Therapeutic Efficacy of telomerase-selective oncolytic adenovirus(OBP-301)and Interleukin-2 in renal cell carcinoma. (2008)
  • Author(s): Peng Huang
  • Organizer: The 5th World Gene Therapy Congress
  • Place of Presentation: Shijiazhuang, China
  • Year and Date: 2008-09-21
• [Presentation] Direct and distant antitumor effects of a telomerase-selective oncolytic adenoviral agent, OBP-301, in a mouse prostate cancer model (2008)
  • Author(s): Huang P
  • Organizer: The second China-Japan Urological Congress
  • Place of Presentation: Kunming,China
  • Year and Date: 2008-09-20
• [Presentation] Direct and distant antitumor effects of a telomerase-selective oncolytic adenoviral agent, OBP-301, in a mouse prostate cancer model. (2008)
  • Author(s): Peng Huang
  • Organizer: The 2nd China-Japan Urological Congress
  • Place of Presentation: Kuming, China
  • Year and Date: 2008-09-20
• [Presentation] REIC/Dkk-3 stable transfectant indicates anti-tumor phentype in mouse prostate cancer RM9 cells (2008)
  • Author(s): Kaku H
  • Organizer: 14^<Th>JSGT
  • Place of Presentation: Sapporo, Japan
  • Year and Date: 2008-06-13
• [Presentation] Synergistic antitumor effects of telomerase-selective oncolytic adenovirus (OBP-301) and interleukin-2 in a mouse renal cell carcinoma model (2008)
  • Author(s): Huang P
  • Organizer: The 11th American Society of Gene Therapy
  • Place of Presentation: Boston,USA
  • Year and Date: 2008-05-29
• [Presentation] Synergistic antitumor effects of telomerase-selective oncolytic adenovirus (OBP-301)and interleukin-2 in a mouse renal cell carcinoma model. (2008)
  • Author(s): Peng Huang
  • Organizer: The 11th the American Societv of Gene Therapy
  • Place of Presentation: Boston, USA
  • Year and Date: 2008-05-29
• [Presentation] The present and futre of gene therapy for prostate cancer inOkayama university (2007)
  • Author(s): Kaku H
  • Organizer: The 1^<st> China-Japan Urological Congress
  • Place of Presentation: Xiamen, China
  • Year and Date: 2007-11-17
• [Presentation] Antitumotelomerase-selective oncolytic adenoviral agents, OBP-301(Telomelysin)in prostate Cancer (2007)
  • Author(s): Peng Hung
  • Organizer: The 24th Korea-Japan Urological Congress
  • Place of Presentation: Cheongju, Korea
  • Year and Date: 2007-10-05
• [Presentation] Telomerase-specific replication-selective virotherapy for prostate cancer (2007)
  • Author(s): 黄 鵬
  • Organizer: 第95回日本泌尿器科学会総会
  • Place of Presentation: 神戸
  • Year and Date: 2007-04-15
• [Presentation] Telomerase-Specific Replication-Selective Virotherapy For Prostate Cancer. (2007)
  • Author(s): Peng Huang
  • Organizer: 日本泌尿器科学会
  • Place of Presentation: 神戸
• [Presentation] Antitumor effect of telomerase-selective oncolytic adenoviral agent, OBP-301 (telomelysion) in prostate cancer. (2007)
  • Author(s): Peng Huang
  • Organizer: 日韓泌尿器科会議
  • Place of Presentation: 韓国
• [Presentation] Telomerase-specific replication-selective virotherapy for prostate cancer (2006)
  • Author(s): 賀来春紀
  • Organizer: 第12回日本遺伝子治療学会
  • Place of Presentation: 東京
  • Year and Date: 2006-08-26
• [Book] 遺伝子治療の最先端泌尿器疾患治療の新しいストラテジー(村井勝, 奥山明彦, 内藤誠二編) (2007)
  • Author(s): 賀来春紀, 那須保友, 公文裕巳
  • Total Pages: 793
  • Publisher: メジカルビューシャ, 東京